Utility Study of Primovist-MRI on HCC Staging

NCT ID: NCT01764438

Last Updated: 2013-01-09

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 174 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2012-08-31
• Study Completion Date: 2013-08-31

Brief Summary

Gadoxetic acid (Gd-EOB-DTPA, Primovist)-enhanced MRI can affect on BCLC staging during the initial staging workups of definite HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.

Detailed Description

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related death worldwide, and its incidence continues to rise even in the Europe and the United States. Recent advancements in early diagnosis and treatment modalities have significantly improved survival in HCC patients, but, only a small portion of them can receive curative treatments. Treatment decision making in HCC is guided by tumor stage, which can be also affected by tumor status at presentation.Thus, intrahepatic tumor status can be pivotal for treatment decision making and for determining prognosis in HCC patients, especially in possible candidates for curative treatment.

The current AASLD guideline recommends that HCC patients with typical HCC ≥1 cm by liver dynamic computed tomography (CT) do not require further investigation to confirm the presence of HCC, and that appropriate treatment can be initiated based on tumor stage. However, other intrahepatic HCC lesion which is not detected by liver dynamic CT can be additionally detected only by Primovist-enhanced MRI.Although few studies have evaluated the usefulness of Primovist-enhanced MRI in HCC patients,most of these studies have been limited by the lack of an evaluation of shift in HCC stage and by the inclusion of patients with suspicious intrahepatic HCC lesions that had been already detected by liver dynamic CT. Furthermore, given the poor prognosis of HCC patients with recurrence after curative treatments such as liver transplantation, surgical resection, or radiofrequency ablation (RFA),accurate staging workup is essential for intrahepatic HCC, especially in patients with a very early or early Barcelona Clinic Liver Cancer (BCLC) staged HCC. To date, however, no evidence based recommendations have been made regarding the benefit of add-on examination of Primovist-enhanced MRI during initial staging workups in HCC patients who are candidates for curative treatment after diagnosis by liver dynamic CT.

In this prospective multicenter study, therefore, we will assess the usefulness of Primovist-enhanced MRI during the initial staging workups of HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT. We will examine whether Primovist-enhanced MRI could provide additional information on BCLC stage, by directly comparing to liver dynamic CT in these patients. Furthermore, we assess whether add-on Primovist-enhanced MRI after a diagnosis of HCC by liver dynamic CT could aid treatment decision making in these patients.

Conditions

Hepatocellular Carcinoma

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

very early or early staged patients

Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious HCC by liver dynamic CT

Primovist-enhanced MRI

Intervention Type: PROCEDURE

Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.

Interventions

Primovist-enhanced MRI

Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.

Intervention Type: PROCEDURE

Other Intervention Names

Gadoxetic acid (Gd-EOB-DTPA, Primovist)-enhancecd MRI

Eligibility Criteria

Inclusion Criteria

• 18 years ≤ age
• Patients who are initially diagnosed as having hepatocellular carcinoma with very early or early BCLC stage by liver dynamic CT at each hospital
• Performance status 0 or 1
• Child-Turcotte-Pugh score ≤8

Exclusion Criteria

• Age of younger than 18
• Patients with any concurrent cancer other than hepatocellular carcinoma. Any cancer curatively treated at least 3 years prior to entry is permitted.
• Patients with BCLC B, C, or D staged HCC at initial diagnosis by liver dynamic CT
• Patients with suspicious intrahepatic malignant lesion by liver dynamic CT
• Patients with HIV infection
• Female patients in pregnancy
• Clinically hemodyanmically unstable patients
• Patients with previous life-threatening anaphylactic reaction to contrast media
• Patients scheduled for biopsy or liver surgery within 24 h post-administration of the study
• Patients who cannot underwent CT due to renal insufficiency (estimated GFR < 30 mL/min/1.73m2)
• Patients who cannot perform MRI due to contraindication of MRI (e.g. an implanted cardiac pacemaker)
• Patients in whom MRI was performed before liver dynamic CT

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Inha University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jin-Woo Lee, M.D.

Role: PRINCIPAL_INVESTIGATOR

Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, Repubulic of Korea

Locations

Jin-Woo Lee

Incheon, , South Korea

Site Status: RECRUITING

Countries

South Korea

Central Contacts

Young-Joo Jin, M.D

Role: CONTACT

jyj412@hanmail.net

82-32-890-2548

Facility Contacts

Jin-Woo Lee, M.D.

Role: primary

jin@inha.ac.kr

82-32-8902548

Other Identifiers

INBU study group

Identifier Type: REGISTRY

Identifier Source: secondary_id

INBU study

Identifier Type: -

Identifier Source: org_study_id